ProBioGen to GlymaxX® to Thermo for Allergy Dx Development
News May 18, 2016
ProBioGen has announced that Thermo Fisher Scientific has licensed its GlymaxX® technology for use in development of allergy diagnostics. ProBioGen’s CSO, Dr. Volker Sandig, comments: “Deviating from the typical GlymaxX® application of enhancing the cell-killing potency of CHO-derived therapeutic antibodies in cancer, GlymaxX® plays out its universal applicability in a radically different field. In this case, GlymaxX® acts to prevent the formation of cross-reactive carbohydrate determinants on recombinant proteins, expressed in insect cells, which would otherwise cause the detection of IgE antibodies of a certain kind with no clinical significance. Thus, this sophisticated technology serves to add to the specificity of the diagnostics test result.”
Dr. Jon-Sverre Schanche, VP R&D for Thermo Fisher’s ImmunoDiagnostics business explains: “Our ImmunoCAP blood tests for allergen-specific IgE antibodies aid clinicians worldwide in their diagnoses of patients with allergy-like symptoms. The GlymaxX® technology will help us in our effort to develop diagnostic tests that deliver even greater clinical precision for the benefit of doctors and allergic patients worldwide.”
ProBioGen’s CEO, Dr. Wieland Wolf, added: “We are very pleased that GlymaxX®, besides its successful therapeutic application, is now employed for diagnostics as well. This proves again the versatile and intelligent solutions GlymaxX® can provide.”
Researchers have used a method to develop a new blood marker capable of detecting whether or not a person has Alzheimer’s disease. If the method is approved for clinical use, the researchers hope eventually to see it used as a diagnostic tool in primary healthcare. This autumn, they will start a trial in primary healthcare to test the technique.